Articles for author: The whipping post

Tesla Q2 EPS Preview: Can Earnings Electrify the Stock?

Tesla Q2 Earnings Zacks Rank #3 (Hold) stock Tesla (TSLA) will report earnings on second quarter earnings results on Wednesday, July 22, after the equity market close. Zacks Consensus Analyst Estimates predict that Tesla will earn $0.50 for Q2, up from the $0.41 the company earning in Q1. Image Source: Zacks Investment Research Tesla’s Recent ...

Berkshire Hathaway's New Leader Has Loaded Up on Alphabet With $10 Billion in Cash. Here's the Likely Reason.

Key Points Alphabet is currently Berkshire Hathaway’s fifth-largest holding. Alphabet is a full-stack AI company. Google Cloud is growing faster than every other major cloud platform. 10 stocks we like better than Alphabet › At the end of last year, Warren Buffett retired as chairman and CEO of Berkshire Hathaway (NYSE: BRKA)(NYSE: BRKB) and passed ...

New Strong Buy Stocks for July 21st

Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today: Adient ADNT: This company which is one of the world’s largest automotive seating suppliers, has seen the Zacks Consensus Estimate for its current year earnings increasing 8.1% over the last 60 days. Adient Price and Consensus Adient price-consensus-chart | Adient Quote ...

Better "Magnificent Seven" Stock: Alphabet vs. Microsoft

Key Points Alphabet is strong in consumer-facing AI, thanks to Gemini integration across the Google ecosystem. Microsoft’s OpenAI relationship has been very profitable, though Copilot has struggled. Investors must ultimately weigh Microsoft’s cheaper valuation and enterprise moat versus Alphabet’s ecosystem and crisp execution to date. 10 stocks we like better than Alphabet › Alphabet (NASDAQ: ...

Netflix's Weak Outlook Overshadows Q2 Earnings Beat: Time to Hold?

Netflix NFLX delivered second-quarter 2026 results that beat the Zacks Consensus Estimate for earnings, yet the streaming giant’s cautious commentary on engagement and margin pressure has left investors questioning whether the stock deserves fresh capital right now or a longer wait on the sidelines. The stock fell more than 8% in after-hours trading on July ...

QURE Stock Outlook Rests on AMT-130, FDA Talks, and Cash Runway

uniQure N.V. QURE remains a catalyst-driven gene therapy stock, with AMT-130 shaping most of the investment debate. The program targets Huntington’s disease, an area where disease-modifying options remain absent. Recent FDA feedback, a targeted biologics license application submission in the third quarter of 2026 and a cash runway into the second half of 2029 now ...